J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated non-small...
Baskin-Robbins has nothing on Vanguard. The ice cream chain is famous for offering 31 flavors to ice cream lovers. Meanwhile, Vanguard's family of exchange-traded funds (ETFs) features 90 choices for investors....
EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END
The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large drugmakers and...
The medical sector is one of the major adopters of artificial intelligence (AI), which is currently being used to synthesize new compounds for drugs and create devices for more precise measurement and...
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication.The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria.C3G...
This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3...
Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.DR-0201 is...
What to invest in now -- that may seem like a tough decision, given the current economic uncertainty in the U.S. including ongoing tariff-related concerns. Investors are worried about inflation, about...
Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic...